Philips, Masimo Bury Hatchet Over Patient-Monitoring Battle
Philips and Masimo have put to rest their long legal wrangling over patient-monitoring technology patents and shaken hands on a multi-year, global sales, and marketing partnership.
You may also be interested in...
Market Intel: Medtronic, Philips, Masimo, And Others Keep Pulse Beating In Oximetry Patient Monitoring Market
Demand for reliable, accurate, high-quality pulse oximetry devices in and – increasingly – outside hospitals is driven by the rise of chronic diseases, a growing elderly population prone to asthma, heart disease, sleep apnea and chronic obstructive pulmonary disease, as well as the need to monitor oxygen levels in premature babies. According to a new report by Meddevicetracker, the global market for standalone, hospital-grade pulse oximetry devices and accessories will reach $1.9bn by 2021, a CAGR of 5.4% from 2016. In this feature, we'll take a closer look at the overall pulse oximetry market, the major players and which forces are driving – and stymying – its growth.
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
A U.S. district court upheld an Oct. 2014 ruling finding Philips guilty of infringing two Masimo patents related to pulse oximetry technology, and awarded $467 million in damages, but Philips is appealing.